Inventiva (IVA) stock
Market cap $893M
Market closed. Prices as of Friday's close.
Members see every stock ranked and every check behind each score, live.
Why IVA scores -1
PoorTrending down, 3 of 13 possible checks firingWhat the Quality Score means
Poor is below 0. Average starts at 6, Above Average at 11, Excellent at 15, and Exceptional at 20.
- +3Momentum traits 3 firing right now, of 13 possible, one point each
- −2Long-term trend below a falling 200‑day, down over one year
- Profit subtractsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
- Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.
No effect today: Run-up, Size, Growth, Dilution, Cash flow, Persistence, and News.
Price, score, traits, and the industry rank are from a snapshot taken at 2:08 PM ET, at least 15 minutes behind. How we rank stocks.
What's next
Reports tomorrow
Mon Nov 23: Revenues and Cash Position UpdateDate confirmed.
2 more dates ahead for members: the conference and the report
What would turn IVA's score around: 6 things, for members
No sign-up. No card. One tap and you're in.
Here is what members see.
Every stock gets a card like this one, and a page with its price in real time, every line of its score, the chart, and its filings.
IVA has 3 of a possible 13 checks firing
14 checks. Two are opposites (heavy volume and quiet volume), so at most 13 are on at once. One per group is shown here.
When does IVA report, and what happens after?
Reports Mon Sep 28 (tomorrow). The company has set the date.
About Inventiva
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.
Every line of the score, on every stock.
- Real-time prices, no delay
- Every line of IVA's score, with the points and the reason
- All 14 checks on IVA and on all 2,961 stocks
- Every stock ranked, with the chart
- Every filing, and optional alerts on IVA
Straight answers.
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Members, trial included, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Where does the data come from?
Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week traits rest on real history. Options flow is not part of the product.
What does it cost?
One plan with everything in it: $29 a month, $69 for three months, or $249 a year. You pick the billing period when the trial ends, and payments go through Stripe, so Breakaway never sees your card.
Is this investment advice?
No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.
The price, the score, the traits, and the industry rank on this page are delayed at least 15 minutes. Filings are shown as filed, because a disclosure is already days or weeks old when it becomes public. Earnings dates and past reactions are settled sessions.